AMOEBA (EPA:ALMIB) - AMOEBA BIOCONTROL PRODUCTS SELECTED BY CERTIS EUROPE FOR EVALUATION ON EUROPEAN VINEYARDS

Transparency directive : regulatory news

30/03/2020 17:45

PRESS RELEASE

AMOEBA BIOCONTROL PRODUCTS SELECTED BY CERTIS EUROPE FOR EVALUATION ON EUROPEAN
VINEYARDS

Chassieu (France), March 30, 2020 - AMOEBA (FR0011051598 - AMEBA), producer of
a biological biocide capable of eliminating the risk in water and human wounds,
and of a biocontrol product for plant protection, still in the testing phase,
announces the signature of a Material Transfer Agreement (MTA) with CERTIS
EUROPE. This new partnership, with a European specialist in crop protection
thanks to its innovative biorational solutions, aims to extend the performance
evaluation of Amoéba's biocontrol products for vines in three European
countries.

Amoeba's provision of its amoeba lysate

The purpose of the research partnership is the delivery by Amoéba of
experimental biocontrol products for crop protection. The amoeba lysate
Willaertia magna C2c Maky, an alternative solution to "all chemical", has
already been tested in 4 European countries through 13 rigorous test
protocols.

Thus, Amoéba offers to CERTIS EUROPE the possibility to access to its patented
technology, result of more than 10 years of research and scientific know-how,
through new formulations.

Tests carried out by CERTIS EUROPE in 3 European countries with significant
vineyards.

In return, CERTIS EUROPE will carry out its own trials in 3 European wine
producing countries:

1) in Italy (1st wine producer in the world(1) and in Germany (8th wine
producer in the world) for field tests,
2) in France for laboratory tests, including rain resistance tests (carried out
on potted vine plants in climatic chamber),
in order to evaluate the performance of these products in preventing downy
mildew diseases on the vine that cause significant yield losses each year.

The development of a real trials network on different grape varieties and under
varied conditions will thus allow the evaluation of various formulations of the
Active Substance (amoeba lysate Willaertia magna C2c Maky).

Amoeba and CERTIS EUROPE are thus embarking on a targeted research phase which
could favor the commercial development of Amoeba's biocontrol solutions if it
proves to be conclusive.

(1) Source OIV 2018

"Certis Europe is one of the leading suppliers of biorational solutions for the
European crop protection markets. It is pleased to partner with Amoeba and has
entered into an agreement to evaluate the efficacy of Amoeba's product based on
the amoeba lysate Willaertia magna C2c Maky on grapes downy mildew (Plasmopora
viticola). Certis Europe has considerable experience and expertise in the
development and marketing of biorational products within integrated pest and
disease management programs that meet the needs of modern agriculture and is
well placed to work alongside Amoeba to assess the potential of this exciting
new product," says Jan Mostert, Head of Biorational innovation of CERTIS
Europe.

"Amoéba is setting up a new partnership at European level with a leading
player in crop protection, whose solutions are recognised by farmers across
Europe. This new agreement reflects the growing interest in our biocontrol
solutions, which are entering a phase of large-scale tests with several
partners and on several applications. These tests have a significant potential
for the company and are an essential step towards a possible commercial
partnership," explains Fabrice Plasson, Chairman and CEO of Amoéba.

Amoéba points out that the company is still in the testing phase for its
biocide and biocontrol applications and does not currently market any
products.

About CERTIS EUROPE
Founded in 2001, Certis Europe was created from three companies acquired by
Mitsui and Co. Ltd during the 1990s in the United Kingdom, France and the
Netherlands. Certis has grown to become a crop protection specialist in Europe.
Its activities include Research and Development, Registration, Sales &
Marketing and Supply Chain Management.
Certis Europe offers expertise on its crop protection products throughout
Europe. Our products combine with those of a range of partners to create an
extensive and diversified portfolio to provide innovative solutions to European
farmers.

Contacts:
CERTIS Europe
Jan Mostert
Head Biorational Innovation Team

Mobile: +31 (0)638056277
Office: +31 (0)302001273
Email: mostert@certiseurope.com
CERTIS EUROPE B.V., Stadsplateau 16, 3521 AZ
Utrecht, The Netherlands
www.certiseurope.com

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com.
(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba
Valérie FILIATRE
General Manager
+33 (0)4 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Investors and Media Relations
Grégory BOSSON / Mathieu CALLEUX
Agence Calyptus
+33(0)1 53 65 37 90
gregory.bosson@calyptus.net

Disclaimer
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the reference
document of AMOEBA filed with the French Financial Markets Authority (Autorité
des Marchés Financiers) on April 25, 2019 under number D19-0383 (a copy of
which is available on www.amoeba-biocide.com). The forward-looking statements
contained in this press release are also subject to risks not yet known to
AMOEBA or not currently considered material by AMOEBA. The occurrence of all or
part of such risks could cause actual results, financial conditions,
performance or achievements of AMOEBA to be materially different from such
forward-looking statements.

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - AMOEBA BIOCONTROL PRODUCTS SELECTED BY CERTIS EUROPE FOR EVALUATION ON EUROPEAN VINEYARDS

Transparency directive : regulatory news

AMOEBA's latest news

Other stories